Opinion

Lernik Ohanjanian: AI as a transformative tool to improve cancer patient outcomes

Photo from Lernik Ohanjanian/LinkedIn

Apr 30, 2024, 16:02

Lernik Ohanjanian: AI as a transformative tool to improve cancer patient outcomes

Lernik Ohanjanian, Senior Medical Director at Miltenyi Biomedicine, shared on LinkedIn:

“We are standing on the cusp of revolution in drug discovery and development, with artificial intelligence (AI) emerging as a transformative tool to improve cancer patient outcomes.

Let’s use AI responsibly in target identification and validation, acceleration of clinical trials, personalization of treatments, enhancing drug formulations, streamlining regulatory approvals and above all improving patient outcomes.”

No alt text provided for this image

Source: Lernik Ohanjanian/LinkedIn

AI in healthcare AI in oncology cancer drug development drug discovery improving patient outcomes Lernik Ohanjanian Miltenyi Biomedicine OncoDaily Oncology

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage